Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
2011
Effects of Epirubicin/Docetaxel Therapy on Plasma Complement in Breast Cancer
publication
Author Information
Author(s): Garantziotis S
Primary Institution: National Institute of Environmental Health Sciences
Hypothesis
The initial dose of epirubicin/docetaxel therapy modulates plasma complement levels in breast cancer patients.
Conclusion
IαI-complement interactions are significant in cancer progression and treatment.
Supporting Evidence
- IαI is not an acute-phase protein and its levels decline during acute inflammation.
- IαI inhibits cancer metastasis and has strong anti-inflammatory properties.
- Increased IαI levels may indicate a regulatory mechanism inhibiting complement activation.
- IαI is being tested in clinical trials for its effect in sepsis.
Takeaway
This study suggests that a protein called IαI might help control inflammation and could be important for treating breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website